H.C. Wainwright Initiates Stemline Therapeutics With Buy

H.C. Wainwright initiated coverage on Stemline Therapeutics Inc STML with a Buy rating. The target price for Stemline Therapeutics is set to $38. Stemline Therapeutics shares have gained 16.51 percent over the past 52 weeks, while the S&P 500 index has surged 13.28 percent in the same period. Stemline Therapeutics' shares fell 2.47 percent to close at $16.58 on Friday.